Preterm Premature Rupture of Membrane
Conditions
Keywords
pentraxin 3, heparin-binding protein, chorioamnionitis, preterm premature rupture of membranes, term premature rupture of membranes
Brief summary
Objective: The aim of this study was to investigate the predictive value of maternal serum pentraxin 3 (PTX3) and heparin-binding protein (HBP) for chorioamnionitis in preterm premature rupture of membranes (PPROM). Method: This observational prospective cohort study included a total of 180 pregnant women at 24-40 gestational weeks. There were 60 cases of term premature rupture of membranes (TPROM), 60 cases of preterm premature rupture of membranes（PPROM）and 60 cases of healthy women. The concentrations of PTX3 and HBP were measured in maternal blood and amniotic fluid using an enzyme-linked immunosorbent assay (ELISA). Western immunoblotting was used to analyze the expression of PTX3 and HBP in placental tissue. The localization and immunoreaction of PTX3 and HBP in placenta were determined via immunohistochemistry (IHC).
Interventions
OTHERThe concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.
The concentrations of PTX3 and HBP were monitored in maternal blood, placental tissue and amniotic fluid.
Sponsors
Second Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. The pregnant woman is born at a gestational age of 24-40 weeks; 2. The pregnant woman has a single child; 3. Regular obstetric examination during pregnancy with complete obstetric examination data was diagnosed as premature rupture of membranes (PROM).
Exclusion criteria
1. Pregnancy complicated with medical and surgical diseases, such as thyroid dysfunction and chronic hypertension; 2. Insufficiency of vital organ function or complicated tumor; 3. Pregnant women with other pregnancy complications besides PROM, such as preeclampsia, etc.; 4. Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease and so on, whether prenatal suspicion or diagnosis postpartum) 5. Neonatal septicemia, hemolytic disease or other diseases affecting bilirubin metabolism.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PTX3 and HBP concentrations in maternal blood | 24 weeks to 40 weeks gestation | PTX3 and HBP concentrations in maternal blood |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PTX3 and HBP concentrations in placental tissue | 24 weeks to 40 weeks gestation | PTX3 and HBP concentrations in placental tissue |
Other
| Measure | Time frame | Description |
|---|---|---|
| PTX3 and HBP concentrations in amniotic fluid | 24 weeks to 40 weeks gestation | PTX3 and HBP concentrations in amniotic fluid |
Outcome results
None listed